Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-35780 BRIGHT HORIZONS FAMILY SOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 80-0188269 (Stat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ____________________________________________________________ Form 10-K ____________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...

Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 SAN DIEGO – February 26, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical- stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025. Corporate Highlights "2025 was a positive year for Revelation with significant advancem ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________to________ Commission File Number: 001-39748 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Class A common stock, $0.0001 par va ...

EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025 RANCHO CUCAMONGA, CA – February 26, 2026 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months and full year ended December 31, 2025. ...

Exhibit 99.1 PondelWilkinson Inc. 2945 Townsgate Road, Suite 200 Westlake Village, CA 91361 Investor Relations T (310) 279 5980 Strategic Public Relations W www.pondel.com CONTACTS: Mark Astrachan SVP, Investor Relations & Corporate Development (951) 739-6200 NEWS RELEASE Roger S. Pondel / Judy Lin PondelWilkinson Inc. (310) 279-5980 MONSTER BEVERAGE REPORTS 2025 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS 2025 Fourth Quarter Highlights The tables at the end of this press release provide a reconciliation ...

Financial Performance - In 2025, the company's revenue was $455.7 million, with a gross margin of 30.0%[22] - The company reported a net loss of $38.2 million in 2025, with accumulated deficits of $493.1 million[22] - The company achieved a compound annual growth rate (CAGR) of 5.7% in annual revenue from 2016 to 2025[212] - The company experienced a net loss of $38.2 million in 2025, with an accumulated deficit of $491.0 million at the end of the year[212] Revenue Sources - The CATV market contributed 53.8% of total revenue in 2025, while the internet data center market accounted for 42.9%[22] - Revenue from the CATV market constituted 53.8% of total revenue in 2025, while the internet data center market contributed 42.9%[212] - The telecom market accounted for 3.0% of total revenue in 2025, a decrease from 4.4% in 2024[213] - The FTTH market contributed only 0.3% of total revenue in 2025, compared to 0.9% in 2024[213] Customer Concentration - Key customer Digicomm represented 53.1% of revenue in 2025, up from 11.3% in 2023[23] - Microsoft was the primary customer in the internet data center market, accounting for 28.8% of revenue in 2025[23] - The top ten customers represented 96.6%, 95%, and 92.7% of revenue for the years ended 2025, 2024, and 2023, respectively, with Digicomm and Microsoft accounting for 53.1% and 28.8% of revenue in 2025[94] Market Trends - The internet data center market is the fastest-growing segment, driven by the demand for higher-capacity optical networking technology[18] - The telecom market is seeing increased demand for optical components due to the deployment of advanced 5G networks[27] - The ongoing deployment of high-speed fiber-optic networks, including 5G, supports growth in the telecom market[211] - The company benefits from trends in higher bandwidth demand across its target markets, including CATV, telecom, and internet data centers[211] Research and Development - The company has a total of 425 employees in the R&D department, including 14 with Ph.D. degrees, and continues to recruit talented engineers[39] - The company engages in an active research and development program to develop new products and enhance existing products, anticipating various releases over the next several years[38] - The company has developed solutions for 25 Gbps and 50 Gbps PON networks, anticipating future adoption by customers[27] - The company has developed proprietary miniaturized optical packaging and electronic control circuitry to create a hybrid WDM-PON solution, addressing historical impediments in fiber-optic deployment[32] Manufacturing and Operations - The company has three manufacturing sites located in Sugar Land, Texas, Ningbo, China, and Taipei, Taiwan, with a focus on vertically integrated manufacturing processes[44] - The company maintains manufacturing and R&D facilities in the U.S., China, and Taiwan, with a total square footage of approximately 2,088,850[198] - In fiscal 2025, 57.5% of the company's revenue, amounting to $262.1 million, was attributable to products manufactured at its plant in China[162] - As of December 31, 2025, 42.8% of the company's property, plant, and equipment was located in China[162] Competitive Landscape - The optical networking market is highly competitive, with major competitors including Coherent Corporation, Intel Corporation, and Lumentum Holdings, among others[56] - The company anticipates increased competition in its product areas, with larger competitors having greater financial and marketing resources[57] Sustainability and Compliance - The company aims to obtain at least 20% of its energy from renewable sources and reduce hazardous waste generation by at least 10% over five years starting in 2024[77] - The company is committed to sustainability initiatives, including improving technology efficiency and exploring alternative energy sources[72] - The company’s operations and products are subject to various environmental regulations, and compliance costs have not been material to its financial position[67] Risks and Challenges - The company faces risks related to the availability, cost, and performance of specialized equipment, which could impact project costs and timelines[87] - If AI adoption slows or does not meet expectations, the company may incur overcapacity and lower utilization rates, negatively affecting margins and free cash flow[88] - The company relies on a limited number of key customers, making it vulnerable to significant reductions in orders from these customers[94] - Changes in government policies and regulatory frameworks could increase project costs and impact the ability to complete or operate facilities as planned[91] - The company may face challenges in recruiting and retaining skilled labor, which is critical for the success of its manufacturing and automation initiatives[87] Intellectual Property - The company owns a total of 199 U.S. issued patents, 140 patents issued in China and Taiwan, and 10 patents issued in Europe, with patents expiring between 2026 and 2046[42] - The company has applied for patents and trademarks to protect its intellectual property, but there is no guarantee of approval or enforcement[171] - The company has taken legal actions to protect its intellectual property, which may lead to significant litigation costs and divert management's attention[174] Financial Position - The company has approximately $163.8 million in consolidated indebtedness as of December 31, 2025[141] - The company reported U.S. accumulated net operating loss carryforwards of approximately $253.0 million, federal and state R&D credits of $14.9 million, and business interest expense carryforwards of $24.9 million as of December 31, 2025[126] - The company has significant foreign currency exposure, particularly to the U.S. dollar, Chinese Renminbi (RMB), and New Taiwan dollar (NT dollar)[127] Cybersecurity - The company has established comprehensive cybersecurity risk management policies and practices to protect customer data and mitigate threats[188] - The board of directors oversees cybersecurity risk management, receiving regular reports on incident prevention and response[194] - The company conducts annual cybersecurity risk assessments to prioritize initiatives for enhancing security controls[190]

Exhibit 99.1 Ambarella, Inc. Announces Fourth Quarter and Fiscal Year 2026 Financial Results February 26, 2026 —Santa Clara, Calif. – Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced fourth quarter and full year fiscal 2026 financial results for the period ended January 31, 2026. Financial results on a non-GAAP basis for the fourth quarter and full year fiscal 2026 are as follows: Quarterly Conference Call Ambarella plans to hold a conference call at 4:30 p.m. Eastern Time / ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Units | TXO | New York Sto ...